Pozelimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Complement C5 |
| Clinical data | |
| Trade names | Veopoz |
| Other names | REGN-3918, pozelimab-bbfg |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623055 |
| License data | |
| Routes of administration | Intravenous, subcutaneous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6418H9898N1690O2026S42 |
| Molar mass | 144496.11 g·mol−1 |
Pozelimab, sold under the brand name Veopoz, is a recombinant monoclonal antibody used for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease. Pozelimab is a complement inhibitor. It is produced using recombinant DNA technology in Chinese hamster ovary cells.
The most common adverse reactions include upper respiratory tract infections, fractures, hives, and alopecia.
Pozelimab was approved for medical use in the United States in August 2023. It is the first FDA-approved treatment for CHAPLE disease. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.